Assessment of signs of influenza illness in the ferret model.

PubWeight™: 3.07‹?› | Rank: Top 1%

🔗 View Article (PMID 2760163)

Published in J Virol Methods on September 15, 1989

Authors

P D Reuman1, S Keely, G M Schiff

Author Affiliations

1: James N. Gamble Institute of Medical Research, Cincinnati, Ohio 45219.

Articles citing this

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis (2008) 11.01

Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88

Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol (2005) 5.40

Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol (2002) 4.87

The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother (2006) 2.69

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother (1998) 2.44

Multiple reassortment between pandemic (H1N1) 2009 and endemic influenza viruses in pigs, United States. Emerg Infect Dis (2011) 2.42

Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J Virol (2009) 2.33

Adaptation of pandemic H1N1 influenza viruses in mice. J Virol (2010) 2.22

Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis (2009) 2.12

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother (2007) 2.03

Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog (2011) 1.87

Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses. PLoS Pathog (2013) 1.83

Does pandemic A/H1N1 virus have the potential to become more pathogenic? MBio (2010) 1.68

Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog (2010) 1.44

Ferrets develop fatal influenza after inhaling small particle aerosols of highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Virol J (2010) 1.36

Subclinical brain injury caused by H5N1 influenza virus infection. J Virol (2011) 1.11

Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology (2010) 1.10

Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine (2009) 1.09

Influenza H1N1 A/Solomon Island/3/06 virus receptor binding specificity correlates with virus pathogenicity, antigenicity, and immunogenicity in ferrets. J Virol (2010) 1.08

Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol (2012) 1.06

Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS One (2011) 1.04

The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. J Virol (2012) 1.01

Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother (2002) 1.00

Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J Virol (2010) 0.98

Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt. Antimicrob Agents Chemother (1990) 0.97

Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness. Front Microbiol (2016) 0.96

Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res (2011) 0.95

Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol (2010) 0.95

Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential. FEMS Microbiol Rev (2015) 0.95

Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model. PLoS One (2012) 0.94

Transcriptome sequencing and development of an expression microarray platform for the domestic ferret. BMC Genomics (2010) 0.93

Differential pathological and immune responses in newly weaned ferrets are associated with a mild clinical outcome of pandemic 2009 H1N1 infection. J Virol (2012) 0.91

Clinical profiles associated with influenza disease in the ferret model. PLoS One (2013) 0.90

Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. PLoS One (2014) 0.88

Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret. Virol J (2010) 0.88

Influenza A virus infection of primary differentiated airway epithelial cell cultures derived from Syrian golden hamsters. Virology (2006) 0.87

Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1. Influenza Other Respir Viruses (2011) 0.86

Rapid emergence of a virulent PB2 E627K variant during adaptation of highly pathogenic avian influenza H7N7 virus to mice. Virol J (2013) 0.85

De-novo transcriptome sequencing of a normalized cDNA pool from influenza infected ferrets. PLoS One (2012) 0.84

A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity. PLoS One (2015) 0.84

A nonlethal young domesticated ferret (Mustela putorius furo) model for studying pandemic influenza virus A/California/04/2009 (H1N1). Comp Med (2010) 0.83

Influenza vaccination accelerates recovery of ferrets from lymphopenia. PLoS One (2014) 0.83

Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume. J Virol (2014) 0.83

Immunity toward H1N1 influenza hemagglutinin of historical and contemporary strains suggests protection and vaccine failure. Sci Rep (2013) 0.82

Early indicators of disease in ferrets infected with a high dose of avian influenza H5N1. Sci Rep (2012) 0.81

Pathogenic influenza B virus in the ferret model establishes lower respiratory tract infection. J Gen Virol (2014) 0.80

Both influenza hemagglutinin and polymerase acidic genes are important for delayed pandemic 2009 H1N1 virus clearance in the ferret model. Virology (2012) 0.80

Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging. ILAR J (2012) 0.79

Influenza A Virus Challenge Models in Cynomolgus Macaques Using the Authentic Inhaled Aerosol and Intra-Nasal Routes of Infection. PLoS One (2016) 0.78

Clinical response to pandemic h1n1 influenza virus from a fatal and mild case in ferrets. Virol J (2015) 0.78

Induction and relief of nasal congestion in ferrets infected with influenza virus. Int J Exp Pathol (1995) 0.78

Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models. Microbiol Mol Biol Rev (2016) 0.78

CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. PLoS One (2011) 0.78

Pathogenesis and Transmission Assessments of Two H7N8 Influenza A Viruses Recently Isolated from Turkey Farms in Indiana Using Mouse and Ferret Models. J Virol (2016) 0.77

Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Vaccine (2015) 0.76

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. PLoS One (2015) 0.76

Peripheral Leukocyte Migration in Ferrets in Response to Infection with Seasonal Influenza Virus. PLoS One (2016) 0.75

Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection. Mol Ther (2017) 0.75

Articles by these authors

Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21

Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis (1986) 1.68

Encephalitis associated with erythema infectiosum. J Pediatr (1970) 1.51

Cell-mediated immunity in humans during viral infection. I. Effect of rubella on dermal hypersensitivity, phytohemagglutinin response, and T lymphocyte numbers. Infect Immun (1974) 1.50

Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus. J Virol (1988) 1.49

Transmission of rubella from newborns. A controlled study among young adult women and report of an unusual case. Am J Dis Child (1965) 1.39

Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis (1990) 1.32

Effect of viral and bacterial pneumonias on cell-mediated immunity in humans. Infect Immun (1976) 1.29

Reye's syndrome: epidemiologic and viral studies, 1963-1974. Am J Epidemiol (1975) 1.28

A study of erythema infectiosum: recovery of rubella virus and echovirus-12. Pediatrics (1972) 1.27

Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis (1991) 1.23

A seroepidemiologic study of a measles epidemic in a highly immunized population. Am J Epidemiol (1972) 1.21

Evidence for natural reassortants of human rotaviruses belonging to different genogroups. J Virol (1990) 1.20

Association of Reye's syndrome with viral infection. Lancet (1974) 1.17

Cellular immune response to cytomegalovirus infection after renal transplantation. Infect Immun (1978) 1.13

Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine (1998) 1.12

Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis (1991) 1.11

Rubella-vaccinated students. Follow-up in a public school system. JAMA (1978) 1.10

Measles IgM response during reinfection of previously vaccinated children. J Pediatr (1973) 1.10

Rubella vaccine evaluation in a public school system. Am J Dis Child (1969) 1.09

Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci U S A (1992) 1.05

Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis (1978) 1.05

Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res (1989) 1.04

Local and systemic antibody response to rotavirus WC3 vaccine in adult volunteers. Antiviral Res (1989) 1.02

Measles antibody in previously immunized children. The need for revaccination. Am J Dis Child (1972) 1.02

Screening hospital patients for hepatitis B surface antigen. Am J Clin Pathol (1977) 1.01

Rubella: recent laboratory and clinical advances. Prog Med Virol (1966) 0.98

Studies on congenital rubella. Preliminary results on the frequency and significance of presence of rubella virus in the newborn and the effect of gamma-globulin in preventing congenital rubella. Am J Dis Child (1965) 0.98

Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus. J Virol (1990) 0.98

Rubella antibody levels in juvenile rheumatoid arthritis. Ann Rheum Dis (1975) 0.97

Protection of adults rechallenged with a human rotavirus. J Infect Dis (1990) 0.97

Fatal viral encephalitis in children with X-linked hypogammaglobulinemia. Am J Dis Child (1973) 0.96

Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Am J Dis Child (1975) 0.96

Experimental rubella studies. I. Clinical and laboratory features of infection caused by the Brown strain rubella virus. II. Artificial challenge studies of adult rubella vaccinees. Am J Dis Child (1969) 0.95

Rubella: studies on the natural disease. The significance of antibody status and communicability among young women. Am J Dis Child (1965) 0.94

Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis (1992) 0.94

Effect of vaccination on serotype-specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection. J Infect Dis (1990) 0.93

Cell-mediated immunity in humans during viral infection: dermal hypersensitivity and in vitro lymphocyte proliferation during mild viral respiratory infections. Infect Immun (1974) 0.91

Prevention of surface-to-human transmission of rotaviruses by treatment with disinfectant spray. J Clin Microbiol (1991) 0.91

Culture adaptation and characterization of group A rotaviruses causing diarrheal illnesses in Bangladesh from 1985 to 1986. J Clin Microbiol (1991) 0.90

Experimental rubella. Clinical and laboratory findings. Arch Intern Med (1965) 0.89

Influenza in ferrets and guinea pigs: effect on cell-mediated immunity. Infect Immun (1978) 0.88

Induction and persistence of local rotavirus antibodies in relation to serum antibodies. J Med Virol (1989) 0.87

A human volunteer challenge model using frozen bacteria of the new epidemic serotype, V. cholerae O139 in Thai volunteers. Vaccine (2001) 0.86

Challenge with rubella virus after loss of detectable vaccine-induced antibody. Rev Infect Dis (1985) 0.86

Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV. J Med Virol (1991) 0.85

Late onset of fatal cytomegalovirus infection after renal transplantation. Primary or reactivation infection? Arch Intern Med (1978) 0.85

Evaluation of a live, attenuated recombinant influenza vaccine in high school children. Infect Immun (1975) 0.85

Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. Am J Dis Child (1969) 0.85

Experimental rubella in pregnant rhesus monkeys. J Infect Dis (1966) 0.83

Herpesvirus hominis type 2 meningoencephalitis following renal transplantation. Am J Med (1976) 0.82

Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus. J Med Virol (1990) 0.82

Comparison of class and subclass antibody response to live and UV-inactivated RSV administered intranasally in mice. J Med Virol (1991) 0.82

Studies of echovirus-12 in volunteers: determination of minimal infectious dose and the effect of previous infection on infectious dose. J Infect Dis (1984) 0.82

Rubella control. Am J Dis Child (1971) 0.82

Detection of viremia by a one step polymerase chain reaction method in hepatitis C virus infection. Virus Res (1993) 0.82

Rubella vaccinees in a public school system: a four and one-half-year follow-up. Am J Dis Child (1974) 0.82

Reye's syndrome. Annu Rev Med (1976) 0.81

Salivary antibody titers in adults challenged with a human rotavirus. J Med Virol (1992) 0.81

Salicylate intoxication and influenza in ferrets. Pediatr Res (1979) 0.80

Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother (1987) 0.80

Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition. Antiviral Res (1990) 0.80

A role for guanylate cyclase C in acid-stimulated duodenal mucosal bicarbonate secretion. Am J Physiol Gastrointest Liver Physiol (2003) 0.79

Maternal-infant transfer of influenza-specific immunity not detectable by haemagglutination inhibition. Microbios (1988) 0.79

Rocky Mountain spotted fever in Clermont County, Ohio: description of an endemic focus. Am J Epidemiol (1973) 0.79

Two-year follow-up of rubella vaccinees in a public school system. Am J Dis Child (1972) 0.78

Follow-up studies of rubella vaccinees at adolescence. J Pediatr (1975) 0.78

Febrile illness in early infancy associated with ECHO virus infection. J Pediatr (1974) 0.77

Isolation and characterization of mouse nasal lymphocytes. J Immunol Methods (1989) 0.77

Ribavirin small-particle-aerosol treatment of influenza B virus infection. Antimicrob Agents Chemother (1988) 0.76

Stability of the rabbit immunogenic marker of RA 27-3 rubella vaccine virus after human passage. Infect Immun (1974) 0.75

Serological survey for rubella and measles antibodies among first graders. JAMA (1974) 0.75

A design for the evaluation of antiviral drugs in human influenza. Am J Epidemiol (1970) 0.75

Evaluation of rubella vaccination in a large school system. J Pediatr (1971) 0.75

Rubella surveillance and immunization among adolescent girls in Cincinnati. Am J Dis Child (1972) 0.75

Wither we goest? Notes of a society watcher plus other comments and thoughts. J Lab Clin Med (1986) 0.75

Evaluation of a trivalent measles, mumps, rubella vaccine in children. J Pediatr (1975) 0.75

Coxsackievirus B epidemic at a boys' camp. Am J Dis Child (1979) 0.75

Letter: Post-transfusion viral infections in Reye syndrome. J Pediatr (1976) 0.75

The effects of cobalt and iodine supplementation of the pregnant ewe diet on immunoglobulin G, vitamin E, T3 and T4 levels in the progeny. Animal (2008) 0.75

Staphylococcus aureus endocarditis. J Lab Clin Med (1971) 0.75

Evaluation of RA 27-3 rubella vaccine. J Pediatr (1974) 0.75

Differential effect of amantadine hydrochloride on the systemic and local immune response to influenza A. J Med Virol (1989) 0.75

Rubella control--1984. J Adolesc Health Care (1984) 0.75

Rubella surveillance and immunization among college women. Obstet Gynecol (1974) 0.75

Rubella and measles serosurvey among a nonurban pediatric population. Am J Dis Child (1975) 0.75

Sewage worker's syndrome. Lancet (1977) 0.75

Proceedings: Rubella surveillance and vaccination at adolescence. Acta Paediatr Scand Suppl (1975) 0.75

Active immunizations for adults. Annu Rev Med (1980) 0.75

Evaluation of influenza A/New Jersey/76 split-product virus vaccine in a summer camp. J Infect Dis (1977) 0.75

Genital viral surveillance among sexually active adolescent girls. J Pediatr (1977) 0.75

Clinical and subclinical rubella following intradermal inoculation of rubella virus into human volunteers. Am J Epidemiol (1966) 0.75

Widespread cutaneous angiolymphoid hyperplasia with eosinophilia. J Dermatol Surg Oncol (1983) 0.75

Rubella surveillance and immunization. Susceptibility in nonurban adolescents. JAMA (1973) 0.75

Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age. Pediatr Infect Dis J (1993) 0.75

Poliovirus antibody in urban school children. J Pediatr (1974) 0.75